Foundayo oral GLP-1 claims: what the FDA approval actually means
Quick answer
The caption claims FDA approval for a drug called Foundayo with 22% weight loss efficacy and 98% intestinal bioavailability, but the actual spoken content of the video contains no clinical information about GLP-1 receptor agonists or weight loss pharmacology. The best available peer-reviewed data on oral semaglutide for obesity (OASIS 1, Knop et al., 2023, The Lancet) shows approximately 15.1% body weight reduction over 68 weeks, which is meaningfully lower than the figure cited in the caption. Patients considering oral versus injectable GLP-1 therapies should consult a licensed provider and review FDA drug approval records directly, as the drug name referenced in this video does not appear in the public FDA approval database.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @drmariohugortizs actually say?
Here is the uncomfortable truth: the transcript does not match the caption at all. The caption promises a breakdown of Foundayo's FDA approval, "~22% weight loss in 48 weeks," and "98% biodisponibilidad intestinal." What the actual spoken transcript delivers is incoherent rambling about oceans, trees, and "the power of the cell" with no mention of Foundayo, GLP-1 receptors, or any clinical data whatsoever.
The video appears to be either a heavily mistranscribed auto-caption from a non-English source, a completely unrelated clip paired with a misleading caption, or a generated or repurposed video. There are zero direct quotes available from the creator that support the specific medical claims in the caption. Any fact-check of those claims has to treat them as caption-only assertions, not as something a medical professional explained on camera.
Does the science back this up?
The underlying clinical claims in the caption are partially grounded in real data, but several numbers appear inflated or unverifiable. Oral semaglutide (brand name Rybelsus) is FDA-approved, but not for weight loss at the doses studied for obesity. The caption's "~22% weight loss" figure does not match published Rybelsus trial outcomes.
The OASIS 1 trial (Knop et al., 2023, The Lancet) tested oral semaglutide at 50 mg daily for obesity and found approximately 15.1% body weight reduction over 68 weeks, not 22% in 48 weeks. The 22% figure is closer to what tirzepatide injections achieved in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). The "98% biodisponibilidad intestinal" claim is unverifiable and inconsistent with known pharmacokinetics of oral GLP-1 agonists. Standard oral semaglutide bioavailability is roughly 0.4-1%, even with the SNAC absorption enhancer. A 98% figure would represent a completely different molecule or delivery mechanism, and no published data supports that number for any approved oral GLP-1 agent.
What did they get wrong (or right)?
The caption gets one thing directionally right: oral GLP-1 formulations are a genuine area of active development, and they would represent a real convenience improvement over injectable therapies. That is a fair observation. The clinical interest is real.
Everything else is a problem. "FDA just approved Foundayo" is not verifiable. As of mid-2025, there is no FDA-approved drug called Foundayo in the public drug approval database. The FDA's drug approval announcements are public record, and no entry matches that name. The 22% weight loss figure appears lifted from injectable tirzepatide data and misattributed to an oral formulation. The 98% bioavailability claim is flatly inconsistent with the published science on oral peptide absorption. Peptides are notoriously difficult to deliver orally precisely because of low bioavailability. No currently approved or late-stage oral GLP-1 agent comes close to 98% intestinal bioavailability. Claiming otherwise misleads patients about what to expect.
What should you actually know?
Oral GLP-1 development is real, ongoing, and worth watching. But the specific claims in this video's caption do not hold up.
- Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes, not obesity, at currently approved doses. Higher-dose formulations for obesity are in trials but not yet approved for that indication in the US as of this writing.
- The best published oral GLP-1 weight loss data shows roughly 15% body weight reduction, not 22%, and that is over a longer timeframe than 48 weeks.
- No oral GLP-1 agent has demonstrated 98% intestinal bioavailability. That figure is not supported by any published pharmacokinetic study.
- The transcript of the actual video contains no medical content. The medical claims exist only in the caption, which means viewers are making health decisions based on text assertions that were never explained or supported on camera.
- If you are evaluating oral versus injectable GLP-1 options, that is a conversation to have with a licensed prescriber who can review your full medical history, not a TikTok caption.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Foundayo oral GLP-1 claims: what the FDA approval actually means, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Foundayo oral GLP-1 claims: what the FDA approval actually means is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The caption claims FDA approval for a drug called Foundayo with 22% weight loss efficacy and 98% intestinal bioavailability, but the actual spoken content of the video contains no clinical information about GLP-1 receptor agonists or weight loss pharmacology.
FormBlends verdict
The caption claims FDA approval for a drug called Foundayo with 22% weight loss efficacy and 98% intestinal bioavailability, but the actual spoken content of the video contains no clinical information about GLP-1 receptor agonists or weight loss pharmacology. The best available peer-reviewed data on oral semaglutide for obesity (OASIS 1, Knop et al., 2023, The Lancet) shows approximately 15.1% body weight reduction over 68 weeks, which is meaningfully lower than the figure cited in the caption. Patients considering oral versus injectable GLP-1 therapies should consult a licensed provider and review FDA drug approval records directly, as the drug name referenced in this video does not appear in the public FDA approval database.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The caption claims FDA approval for a drug called Foundayo with 22% weight loss efficacy and 98% intestinal bioavailability, but the actual spoken content of the video contains no clinical information about GLP-1 receptor agonists or weight loss pharmacology. The best available peer-reviewed data on oral semaglutide for obesity (OASIS 1, Knop et al., 2023, The Lancet) shows approximately 15.1% body weight reduction over 68 weeks, which is meaningfully lower than the figure cited in the caption. Patients considering oral versus injectable GLP-1 therapies should consult a licensed provider and review FDA drug approval records directly, as the drug name referenced in this video does not appear in the public FDA approval database.
- No drug named Foundayo appears in the FDA's public drug approval database as of mid-2025. Verify any claimed FDA approval directly at fda.gov before acting on it.
- OASIS 1 (Knop et al., 2023, The Lancet) found oral semaglutide 50 mg produced about 15.1% weight loss over 68 weeks, not 22% in 48 weeks as the caption states.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- No drug named Foundayo appears in the FDA's public drug approval database as of mid-2025. Verify any claimed FDA approval directly at fda.gov before acting on it.
- OASIS 1 (Knop et al., 2023, The Lancet) found oral semaglutide 50 mg produced about 15.1% weight loss over 68 weeks, not 22% in 48 weeks as the caption states.
- The 22% weight loss figure matches injectable tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM), suggesting the caption may have mixed up drug classes or delivery routes.
- Oral peptide bioavailability is a known pharmacological challenge. Standard oral semaglutide sits around 0.4-1% absorption. A 98% bioavailability claim for any oral GLP-1 agent is not supported by any published study.
- The actual spoken transcript of this video contains no medical claims about GLP-1 drugs, weight loss, or Foundayo. The medical assertions exist only in the caption.
- Oral GLP-1 development is a legitimate and active research area, but no currently approved oral GLP-1 therapy in the US is labeled for obesity at the efficacy levels injectable semaglutide or tirzepatide achieve.
- Always cross-reference drug approval claims with FDA.gov and discuss treatment options with a licensed prescriber who has access to your complete medical history.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
drmariohugortizs · TikTok creator
67.8K views on this video
La FDA acaba de aprobar Foundayo y esto lo cambia TODO 🧬💊 Una pastilla oral que en estudios clínicos logró ~22% de pérdida de peso corporal en 48 semanas. Sin agujas. Sin cadena de frío. 98% de biodisponibilidad intestinal. ¿Será el sucesor real de la era inyectable? Te lo explico en 60 segundos 👇 Guarda este video porque vas a querer volver a verlo. Hashtags: #foundayo
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by drmariohugortizs, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.